Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry - 09/12/21
Abstract |
Background |
Psoriasis is associated with comorbid systemic metabolic disease.
Objective |
To assess possible associations of comorbid obesity, history of diabetes, hypertension, and hyperlipidemia with response to biologic treatment at 6 months among patients in CorEvitas' Psoriasis Registry.
Methods |
Participants included 2924 patients initiating biologic therapy (tumour necrosis factor inhibitors [TNFi], interleukin [IL]-17i, IL-12/23i, or IL-23i) with baseline and 6-month follow-up visits available. Logistic regressions resulted in adjusted odd ratios (OR) and 95% confidence intervals (CI) for achievement of response in select outcomes for those with obesity and history of diabetes, hypertension, and hyperlipidemia relative to those without each.
Results |
Overall, obesity reduced by 25% to 30% odds of achieving PASI75 (OR, 0.75; 95% CI, 0.64-0.88) and PASI90 (OR, 0.70; 95% CI, 0.59-0.81). History of diabetes reduced odds of achieving PASI75 by 31% (OR, 0.69; 95% CI, 0.56-0.85) and PASI90 by 21% (OR, 0.79; 95% CI, 0.63-0.98). Obesity was associated with lower response to TNFi and IL-17i classes. Independent of obesity, diabetes was associated with poorer outcomes when on IL-17i therapy and hypertension, to a lesser extent, when on the TNFi class. No significant associations were found in the hyperlipidemia group.
Limitations |
The study assessed only short-term effectiveness and small sample sizes limited the power to detect differences.
Conclusion |
Assessment of comorbid disease burden is important for improved likelihoods of achieving treatment response with biologics.
Le texte complet de cet article est disponible en PDF.Key words : biologics, biologic therapy, comorbid disease, metabolic disease, outcomes, psoriasis, psoriatic disease, treatment response
Abbreviations used : BSA, CI, DM, HTN, HLD, IGA, IL, OR, PASI, TNF
Plan
| Funding sources: Sponsored by CorEvitas (formerly Corrona) LLC and the analysis was funded by CorEvitas LLC. Access to study data was limited to CorEvitas. CorEvitas statisticians completed all of the analysis. All authors contributed to the interpretation of the results. CorEvitas has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, ARENA, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, LEO, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Sanofi, SUN, and UCB. This study was supported through a partnership between CorEvitas and the National Psoriasis Foundation. |
|
| IRB approval status: Exempt. |
|
| Reprints not available from the authors. |
Vol 86 - N° 1
P. 68-76 - janvier 2022 Retour au numéro
Article précédent
- Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa
- Surav Man Sakya, David R. Hallan, Steven A. Maczuga, Joslyn S. Kirby
- Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
- Linda Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Mindy Chen, Maria Paris, Yao Wang, Kristina Callis Duffin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?